Table 3.
Clinical implication of miR-1224 in human cancers.
| Systems | Cancer type | Aggressive phenotype of low miR-1224 | OS of low miR-1224 | Therapeutic target | Drug resistance | References |
|---|---|---|---|---|---|---|
| Respiratory system | LC | Yes | Poor | Yes | / | (19) |
| LP | / | / | Yes | / | (20) | |
| LAUD | / | Poor | Yes | / | (21) | |
| Nerve system | LGG | / | Poor | Yes | / | (22) |
| Glioma | High grade | Poor | Yes | / | (24) | |
| GBM | / | Poor | Yes | PDGF receptor resistance | (25) | |
| Muscular and skeletal systems | OS | / | Poor | Yes | / | (27) |
| Genitourinary system | BCa | High TNM stage | Poor | Yes | / | (29) |
| BC | / | Good | Yes | / | (32) | |
| Digestive system | TSCC | / | Poor | / | / | (33) |
| OSCC | / | Poor | / | 5-FU resistance | (34) | |
| GC | / | Poor | Yes | / | (35) | |
| CRC | Yes | Poor | Yes | / | (39) | |
| ESCC | High grade | Poor | Yes | EGFR resistance | (40) | |
| HCC | High TNM stage | Poor | Yes | / | (42) | |
| PC | High TNM stage | Poor | Yes | / | (45) | |
| Skin | Melanoma | High TNM stage | Poor | Yes | / | (47) |
| keloids | / | Poor | Yes | / | (48) |